Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer

Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer

Abstract Background To profile genomic and epigenomic of a naïve Chinese non-small cell lung cancer (NSCLC) cohort and investigate the association between tumor mutation burden (TMB) and DNA methylation (DNAm) to explore potential alternative/complimentary biomarkers for NSCLC immunotherapies. Metho...

Full description

Bibliographic Details
Main Authors:	Liangliang Cai, Hua Bai, Jianchun Duan, Zhijie Wang, Shugeng Gao, Di Wang, Shuhang Wang, Jun Jiang, Jiefei Han, Yanhua Tian, Xue Zhang, Hao Ye, Minghui Li, Bingding Huang, Jie He, Jie Wang
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2019-07-01
Series:	Journal for ImmunoTherapy of Cancer
Subjects:	Genetics Epigenetics Non-small cell lung cancer Tumor mutation burden Checkpoint inhibitor therapy
Online Access:	http://link.springer.com/article/10.1186/s40425-019-0660-7

Similar Items

Predictive Value of Tumor Mutation Burden in Immunotherapy for Lung Cancer
by: Huanlan SA, et al.
Published: (2019-06-01)

Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma
by: Wang H, et al.
Published: (2021-05-01)

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age
by: Yongfeng Wu, et al.
Published: (2020-04-01)

The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
by: Yongfeng Wu, et al.
Published: (2019-11-01)

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden
by: Jan Budczies, et al.
Published: (2018-12-01)

Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival
by: Yanmei Gao, et al.
Published: (2020-10-01)

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy
by: Peipei Wang, et al.
Published: (2021-04-01)

Identification and validation of a miRNA-related expression signature for tumor mutational burden in colorectal cancer
by: Lijun Xu, et al.
Published: (2021-02-01)

Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
by: Taobi Huang, et al.
Published: (2021-07-01)

Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer
by: Apostolos Zaravinos, et al.
Published: (2019-08-01)

Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer
by: Jinchul Kim, et al.
Published: (2020-03-01)

A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer
by: Jian Xiao, et al.
Published: (2021-03-01)

Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis
by: Yan Li, et al.
Published: (2021-09-01)

De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma
by: Si-Cong Ma, et al.
Published: (2021-06-01)

Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer
by: Lijuan Wang, et al.
Published: (2021-02-01)

Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT‐based radiomics signature
by: Xiaoxiao Wang, et al.
Published: (2019-10-01)

Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non‐small cell lung cancer
by: Li‐Yue Sun, et al.
Published: (2021-10-01)

Determining mutational burden and signature using RNA-seq from tumor-only samples
by: Erik Jessen, et al.
Published: (2021-03-01)

A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma
by: Luochengling Xiang, et al.
Published: (2020-09-01)

Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories
by: Ping Qiu, et al.
Published: (2016-04-01)

Repeat-induced point mutation in Neurospora crassa causes the highest known mutation rate and mutational burden of any cellular life
by: Long Wang, et al.
Published: (2020-06-01)

Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
by: Timothy V. Pham, et al.
Published: (2020-08-01)

Designing gene panels for tumor mutational burden estimation: the need to shift from ‘correlation’ to ‘accuracy’
by: Hao-Xiang Wu, et al.
Published: (2019-08-01)

FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer
by: Zixin Guo, et al.
Published: (2021-03-01)

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors
by: Yu Chen, et al.
Published: (2020-09-01)

Tumor mutational burden is not predictive of cytotoxic chemotherapy response
by: Mina Nikanjam, et al.
Published: (2020-01-01)

NIMBus: a negative binomial regression based Integrative Method for mutation Burden Analysis
by: Jing Zhang, et al.
Published: (2020-10-01)

Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma
by: Rui Zhang, et al.
Published: (2021-02-01)

miRNA-Based Signature Associated With Tumor Mutational Burden in Colon Adenocarcinoma
by: Weijie Xue, et al.
Published: (2021-06-01)

Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma
by: Xiao-Hong Xie, et al.
Published: (2020-07-01)

Tumor mutation burden: from comprehensive mutational screening to the clinic
by: Francesca Galuppini, et al.
Published: (2019-08-01)

High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas
by: Ping Mei, et al.
Published: (2020-05-01)

From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy
by: Andrea Sesma, et al.
Published: (2020-10-01)

ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1–SHP2 Signaling Pathway in Non-Small Cell Lung Cancer
by: Liangliang Cai, et al.
Published: (2020-11-01)

Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
by: Mary A. Wood, et al.
Published: (2020-03-01)

Correlate tumor mutation burden with immune signatures in human cancers
by: Xiaosheng Wang, et al.
Published: (2019-01-01)

Research Progress on Heterogeneity of Tumor Mutation Burden in Patients with  Non-small Cell Lung Cancer
by: Abdurazik MIHRAY, et al.
Published: (2021-04-01)

Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
by: Hao Chen, et al.
Published: (2019-05-01)

Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?
by: Hana Noskova, et al.
Published: (2020-01-01)

Significance of tumor mutation burden and immune infiltration in thymic epithelial tumors
by: Zi‐Ming Wang, et al.
Published: (2021-07-01)